Therapy of Acute Myeloid Leukemia
January 2012
in “
InTech eBooks
”
Studysummary In this study, higher doses of daunorubicin during induction therapy significantly improved complete remission rates in young adults with acute myeloid leukemia.
Our plain-language summary. Not medical advice or a treatment recommendation. Consult a qualified healthcare professional before changing treatment. Full disclaimer
Acute myeloid leukemia (AML) was the most common acute leukemia in adults, with less than one-third of patients being curable. Standard induction therapy typically included daunorubicin (DNR) and cytarabine, achieving complete remission (CR) rates of 60%-80% in young adults and 40%-60% in older adults. Studies showed that higher doses of DNR (90 mg/m²) improved CR rates and overall survival (OS) in younger patients, but not significantly in older patients. Liposomal formulations like CPX-351 reduced non-hematologic toxicities while maintaining efficacy. Despite advancements, treating refractory, relapsed, and elderly AML remained challenging, necessitating ongoing research into new regimens and targeted therapies.
